Hypertension and endothelial dysfunction: Therapeutic approach

Current Vascular Pharmacology

Volumn 10, Issue 1, 2012, Pages 42-60

  Ghiadoni, Lorenzo ^a   Taddei, Stefano ^a   Virdis, Agostino ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Endothelium; Hypertension; Large arteries; Microcirculation; Nitric oxide; Therapy

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CANDESARTAN; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLAVANOL DERIVATIVE; HYDROCHLOROTHIAZIDE; INTERCELLULAR ADHESION MOLECULE 1; LACIDIPINE; LERCANIDIPINE; LOSARTAN; METOPROLOL; NIFEDIPINE; NITRIC OXIDE; NITRITE; OMEGA 3 FATTY ACID; POLIFENOL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; THROMBOMODULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

AEROBIC EXERCISE; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; AUTOCRINE EFFECT; BLOOD FLOW; BLOOD VESSEL REACTIVITY; CACAO; CARDIOVASCULAR RISK; CELL FUNCTION; CIRCULATION; CORONARY ARTERY BLOOD FLOW; DIET SUPPLEMENTATION; DYNAMIC EXERCISE; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; NONHUMAN; OUTCOME ASSESSMENT; PARACRINE SIGNALING; RED WINE; REVIEW; TEA; THERAPY EFFECT; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MICROCIRCULATION; NITRIC OXIDE; OXIDATIVE STRESS; VASOMOTOR SYSTEM;

EID: 84857135135     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112798829823     Document Type: Review

References (181)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
2. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20: II-3-10.
3. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337-49.
4. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999; 100: 1400-5.
5. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
6. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 7-17.
7. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
8. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-8.
9. Virdis A, Ghiadoni L, Versari D, Giannarelli C, Salvetti A, Taddei S. Endothelial function assessment in complicated hypertension. Curr Pharm Des 2008; 14: 1761-70.
10. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
11. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-9.
12. Ghiadoni L, Versari D, Magagna A, et al. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 2007; 25: 361-6.
13. Ghiadoni L, Huang Y, Magagna A, Buralli S, Taddei S, Salvetti A. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 2001; 19: 547-51.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
15. Ghiadoni L, Donald AE, Cropley M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000; 102: 2473-8.
16. Gemignani V, Bianchini E, Faita F, et al. Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating. Ultrasound Med Biol 2008; 34: 385-91.
17. Gemignani V, Faita F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of the brachial artery diameter in Bmode ultrasound images. IEEE Trans Med Imaging 2007; 26: 393-404.
18. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse-wave analysis: clinical evaluation of a non-invasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002; 22: 147-52.
19. Chowienczyk PJ, Kelly RP, MacCallum H, et al. Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J Am Coll Cardiol 1999; 34: 2007-14.
20. Quyyumi AA, Cannon RO, 3rd, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 1992; 86: 1864-71.
21. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endotheliummediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
22. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endotheliumdependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995; 25: 201-6.
23. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
24. Frielingsdorf J, Kaufmann P, Seiler C, Vassalli G, Suter T, Hess OM. Abnormal coronary vasomotion in hypertension: role of coronary artery disease. J Am Coll Cardiol 1996; 28: 935-41.
25. Nitenberg A, Antony I, Aptecar E, Arnoult F, Lerebours G. Impairment of flow-dependent coronary dilation in hypertensive patients. Demonstration by cold pressor test induced flow velocity increase. Am J Hypertens 1995; 8: 13S-18S.
26. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
27. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
28. Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension 1996; 28: 505-6.
29. Schiffrin EL. Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension. J Hypertens 1995; 13: 817-21.
30. Goodhart DM, Anderson TJ. Role of nitric oxide in coronary arterial vasomotion and the influence of coronary atherosclerosis and its risks. Am J Cardiol 1998; 82: 1034-9.
31. Versari D, Lerman LO, Lerman A. The importance of reendothelialization after arterial injury. Curr Pharm Des 2007; 13: 1811-24.
32. Rassaf T, Feelisch M, Kelm M. Circulating NO pool: assessment of nitrite and nitroso species in blood and tissues. Free Radic Biol Med 2004; 36: 413-22.
33. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
34. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005;43:1124-9.
35. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Int J Clin Chem 2006; 368: 33-47.
36. Gimbrone MA, Jr., Cybulsky MI, Kume N, Collins T, Resnick N. Vascular endothelium. An integrator of pathophysiological stimuli in atherogenesis. Annals of the New York Academy of Sciences 1995; 748: 122-31.
37. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12: 925-8.
38. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-41.
39. DeCaterina R, Ghiadoni L, Taddei S, et al. Soluble E-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 2001; 14: 259-66.
40. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thrombosis and haemostasis 1991; 65: 618-23.
41. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thrombosis and haemostasis 1998; 79: 456-65.
42. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovascular research 1997; 34: 255-65.
43. Goon PK, Boos CJ, Lip GY. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 2005; 51: 531-8.
44. Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003; 93: 980-9.
45. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-78.
46. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
47. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-51.
48. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-7.
49. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29: 736-43.
50. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18: 363-74.
51. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endotheliumdependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74.
52. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restrores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274-9.
53. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-9.
54. Marzilli M, Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial function and coronary microcirculaiton in essential hypertension. J Hypertens 1998; 16 (suppl 8): S59-S63.
55. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
56. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33.
57. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
58. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 2004; 49: 525-33.
59. Taddei S, Versari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol 2006; 48: 508-15.
60. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996; 14: 1247-55.
61. Rizzoni D, Muiesan ML, Porteri E, et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997; 15: 197-204.
62. Rizzoni D, Porteri E, Castellano M, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998; 31: 335-41.
63. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
64. Endemann DH, Pu Q, De Ciuceis C, et al. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension 2004; 43: 399-404.
65. Rizzoni D, Porteri E, De Ciuceis C, et al. Lack of prognostic role of endothelial dysfunction in subcutaneous small resistance arteries of hypertensive patients. J Hypertens 2006; 24: 867-73.
66. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.
67. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
68. Witte DR, Westerink J, de Koning EJ, van der Graaf Y, Grobbee DE, Bots ML. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol 2005; 45: 1987-93.
69. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94.
70. Ghiadoni L, Taddei S, Virdis A, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32: 25-32.
71. Hashimoto M, Eto M, Akishita M, et al. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol 1999; 19: 2795-800.
72. Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004; 110: 2918-23.
73. Campuzano R, Moya JL, Garcia-Lledo A, et al. Endothelial dysfunction, intima-media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis. J Hypertens 2006; 24: 1581-8.
74. Rundek T, Hundle R, Ratchford E, et al. Endothelial dysfunction is associated with carotid plaque: a cross-sectional study from the population based Northern Manhattan Study. BMC Cardiovasc Disord 2006; 6: 35.
75. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005; 45: 1980-6.
76. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-93.
77. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-9.
78. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endotheliumdependent vasodilation in never-treated hypertensive patients. Circulation 1999; 99: 1991-6.
79. Ercan E, Tengiz I, Ercan HE, Nalbantgil I. Left ventricular hypertrophy and endothelial functions in patients with essential hypertension. Coron Artery Dis 2003; 14: 541-4.
80. Muiesan ML, Salvetti M, Monteduro C, et al. Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. J Hypertens 2001; 19: 641-7.
81. Sciacqua A, Scozzafava A, Pujia A, et al. Interaction between vascular dysfunction and cardiac mass increases the risk of cardiovascular outcomes in essential hypertension. Eur Heart J 2005; 26: 921-7.
82. Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. J Cardiovasc Pharmacol 2006; 47 Suppl 2: S151-62.
83. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
84. Diercks GF, Stroes ES, van Boven AJ, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flowmediated vasodilation, in apparently healthy subjects. Atherosclerosis 2002; 163: 121-6.
85. Taddei S, Virdis A, Mattei P, et al. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. J Hypertens 1995; 13: 1003-8.
86. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
87. Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17: 512-9.
88. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
89. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant 2000; 15: 1194-200.
90. Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57: 10-5.
91. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-52.
92. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 512-8.
93. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-52.
94. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435-46.
95. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
96. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57: 244-52.
97. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
98. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004; 110: 821-5.
99. van der Harst P, Smilde TD, Buikema H, et al. Vascular function and mild renal impairment in stable coronary artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 379-84.
100. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
101. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109: 613-9.
102. Taddei S, Galetta F, Virdis A, et al. Physical activity prevents agerelated impairment in nitric oxide availability in elderly athletes. Circulation 2000; 101: 2896-901.
103. Franzoni F, Ghiadoni L, Galetta F, et al. Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 2005; 18: 510-6.
104. Clarkson P, Montgomery HE, Mullen MJ, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999; 33: 1379-85.
105. Higashi Y, Sasaki S, Kurisu S, et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endotheliumderived nitric oxide. Circulation 1999; 100: 1194-202.
106. DeSouza CA, Shapiro LF, Clevenger CM, et al. Regular aerobic exercise prevents and restores age-related declines in endotheliumdependent vasodilation in healthy men. Circulation 2000; 102: 1351-7.
107. Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000; 35: 706-13.
108. Duffy SJ, Gokce N, Holbrook M, et al. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 2001; 280: H528-34.
109. Simons LA, von Konigsmark M, Simons J, Stocker R, Celermajer DS. Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis 1999; 143: 193-9.
110. Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and e improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 392-7.
111. Grassi D, Necozione S, Lippi C, et al. Cocoa reduces blood pressure and insulin resistance and improves endotheliumdependent vasodilation in hypertensives. Hypertension 2005; 46: 398-405.
112. Duffy SJ, Keaney JF, Jr., Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-6.
113. Hodgson JM, Puddey IB, Burke V, Watts GF, Beilin LJ. Regular ingestion of black tea improves brachial artery vasodilator function. Clin Sci (Lond) 2002; 102: 195-201.
114. Grassi D, Mulder TP, Draijer R, Desideri G, Molhuizen HO, Ferri C. Black tea consumption dose-dependently improves flowmediated dilation in healthy males. J Hypertens 2009; 27: 774-81.
115. Flesch M, Schwarz A, Bohm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998; 275: H1183-90.
116. Hashimoto M, Kim S, Eto M, et al. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am J Cardiol 2001; 88: 1457-60, A9.
117. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100: 1050-5.
118. Goode GK, Garcia S, Heagerty AM. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 1997; 96: 2802-7.
119. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-70.
120. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 1999; 33: 633-40.
121. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000; 102: 1264-9.
122. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2: 64-70.
123. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123-8.
124. Yamanari H, Nakamura K, Miura D, Yamanari S, Ohe T. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress. Clin Exp Hypertens 2009; 31: 585-94.
125. Chung NA, Beevers DG, Lip G. Effects of losartan vs. hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press 2004; 13: 183-9.
126. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
127. Taddei S, Virdis A, Ghiadoni L, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19: 1379-86.
128. Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan vs. metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant. 2008; 23: 2280-5.
129. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an Larginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.
130. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-4.
131. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol 2006; 48: 862-9.
132. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-52.
133. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008; 21: 1251-7.
134. Feuerstein GZ, Ruffolo RR, Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl F: 38-42.
135. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol vs. metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007; 20: 777-83.
136. Nishioka K, Nakagawa K, Umemura T, et al. Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy. Heart 2007; 93: 247-8.
137. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 265-84.
138. Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996; 93: 1380-7.
139. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107: 422-8.
140. Luscher TF, Pieper M, Tendera M, et al. A randomized placebocontrolled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009; 30: 1590-7.
141. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008; 30: 267-76.
142. Muiesan ML, Salvetti M, Monteduro C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999; 33: 575-80.
143. Koh KK, Han SH, Ahn JY, Chung WJ, Lee Y, Shin EK. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol 2009; 133: 23-31.
144. Sugiura T, Kondo T, Kureishi-Bando Y, et al. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 2008; 52: 491-8.
145. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30: 1606-12.
146. Sudano I, Virdis A, Taddei S, et al. Chronic treatment with longacting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Hypertension 2007; 49: 285-90.
147. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41: 950-5.
148. Perticone F, Ceravolo R, Maio R, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. Cardiovasc Res 1999; 41: 299-306.
149. Versari D, Virdis A, Ghiadoni L, et al. Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients. Atherosclerosis 2009; 205: 214-20.
150. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70: 1099-103.
151. Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37: 943-8.
152. Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, doubleblind study. Cardiovasc Ther 2009; 27: 151-8.
153. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22: 535-42.
154. Virdis A, Colucci R, Fornai M, et al. Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension 2007; 49: 679-86.
155. Schiffrin EL, Deng LY. Comparison of effects of angiotensin Iconverting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25: 699-703.
156. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor testinduced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115-22.
157. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
158. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-6.
159. Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and nonsulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 443-50.
160. Mimran A, Ribstein J, DuCailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension 1995; 26: 937-41.
161. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505.
162. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996; 27: 371-6.
163. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endotheliumdependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16: 447-56.
164. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004; 17: 1192-200.
165. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with non-insulin-dependent diabetes mellitus. Hypertension 2005; 45: 659-65.
166. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002; 20: 71-8.
167. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501-6.
168. Bellien J, Iacob M, Eltchaninoff H, Bourkaib R, Thuillez C, Joannides R. AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans. Clin Sci (Lond) 2007; 112: 393-401.
169. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Boger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50: 367-71.
170. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799-805.
171. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449-56.
172. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52: 563-72.
173. Morimoto S, Maki K, Aota Y, Sakuma T, Iwasaka T. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function. Hypertens Res 2008; 31: 1603-10.
174. Ghiadoni L, Magagna A, Kardasz I, Taddei S, Salvetti A. Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hpertens 2009; 22: 506-12.
175. Perrone-Filardi P, Corrado L, Brevetti G, et al. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich) 2009; 11: 260-5.
176. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
177. John S, Delles C, Jacobi J, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37: 1351-8.
178. Tousoulis D, Papageorgiou N, Androulakis E, Paroutoglou K, Stefanadis C. Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Exp Opin Invest Drugs 2010; 19: 1395-412.
179. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96: 1513-9.
180. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
181. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-10.